TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer

Cancer Research

Volumn 69, Issue 12, 2009, Pages 5049-5056

  Helms, Mike W ^a   Kemming, Dirk ^b   Contag, Christopher H ^a   Pospisil, Heike ^c   Bartkowiak, Kai ^b   Wang, Alice ^d   Chang, Sheng Yung ^d   Buerger, Horst ^e   Brandt, Burkhard H ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d CELERA   (United States)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN TOB1; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CALCIUM SIGNALING; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSKELETON; DISTANT METASTASIS; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CALCIUM SIGNALING; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 67449128462     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4154     Document Type: Article

References (50)

1. Torregrosa D, Bolufer P, Lluch A, et al. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta 1997;262:99-119. (Pubitemid 27241382)
2. Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K. The relationship between human epidermal growthlike factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem 1996;271:30897-30903 (Pubitemid 26404114)
3. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 2003;133:219-221 (Pubitemid 36407987)
4. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987;1:1398-1402 (Pubitemid 17078859)
5. Lacroix H, Iglehart JD, Skinner MA, Kraus MH. Overexpression of Erbb-2 or EGF receptor proteins present in early stage mammary-carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 1989;4:145-151 (Pubitemid 19096937)
6. Suo Z, Emilsen E, Tveit KM, Nesland JM. Type 1 protein tyrosine kinases in benign and malignant breast lesions. Histopathology 1998;33:514-521 (Pubitemid 28563376)
7. Tovey SM, Witton CJ, Bartlett JMS, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004;6:R246-51.
8. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of C-Erbb-2 expression in breast cancer. J Clin Oncol 1992;10:1049-1056
9. Muss HB, Thor AD, Berry DA, et al. C-Erbb-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266 (Pubitemid 24129958)
10. Arpino G, Green SJ, Allred DC, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. Clin Cancer Res 2004;10:5670-5676
11. Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 1999;253:78-87.
12. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001;6:393-406. (Pubitemid 39600497)
13. Eccles SA. Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. Recent Results Cancer Res 2000;157:41-54.
14. Feldner JC, Brandt BH. Cancer cell motility-on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res 2002;272:93-108. (Pubitemid 34920677)
15. Segall JE, Tyerech S, Boselli L, et al. EGF stimulates lamellipod extension in metastatic mammary adenocarcinoma cells by an actin-dependent mechanism. Clin Exp Metastasis 1996;14:61-72. (Pubitemid 26008960)
16. Zhang M, Singh RK, Wang MH, Wells A, Siegal GP. Epidermal growth factor modulates cell attachment to hyaluronic acid by the cell surface glycoprotein CD44. Clin Exp Metastasis 1996;14:268-276 (Pubitemid 26246572)
17. Shibata T, Ochiai A, Kanai Y, et al. Dominant negative inhibition of the association between β-catenin and c-erbB-2 by N-terminally deleted β-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 1996;13:883-889 (Pubitemid 26329074)
18. Roetger A, Merschjann A, Dittmar T, Jackisch C, Barnekow A, Brandt B. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. Am J Pathol 1998;153:1797-1806 (Pubitemid 28550667)
19. O'charoenrat P, Eccles S, Court W, Box G, Modjtahedi H, Dean C. Differential up-regulation of MMP-9 in squamous cell carcinomas of head and neck by EGFR ligands. Br J Cancer 1998;78:15.
20. Watabe T, Yoshida K, Shindoh M, et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998;77:128-137 (Pubitemid 28308562)
21. Dittmar T, Husemann A, Schewe Y, et al. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of cerbB-2 receptor via epidermal growth factor receptor. FASEB J 2002;16:1823-1825
22. Diatchenko L, Lau YF, Campbell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci U S A 1996;93:6025-6030 (Pubitemid 26190796)
23. Roetger A, Merschjann A, Dittmar T, Jackisch C, Barnekow A, Brandt B. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. Am J Pathol 1998;153:1797-1806 (Pubitemid 28550667)
24. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-3402 (Pubitemid 27359211)
25. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847 (Pubitemid 28331029)
26. Packeisen J, Buerger H, Krech R, Boecker W. Multi tissue arrays - a new approach for quality control in immunohistochemistry. J Clin Pathol 2002;55:613-615 (Pubitemid 34888306)
27. Korsching E, Packeisen J, Liedtke C, et al. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005;206:451-457
28. Rogge L, Bianchi E, Biffi M, et al. Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet 2000;25:96-101. (Pubitemid 30257045)
29. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826 (Pubitemid 40051905)
30. Brandt BH, Roetger A, Dittmar T, et al. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J 1999;13:1939-1949 (Pubitemid 29517624)
31. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet 2005;365:671-679 (Pubitemid 40260888)
32. Sørlie T, Perou C, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874 (Pubitemid 32878711)
33. Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002;196:17-25. (Pubitemid 34071574)
34. Toi M, Tominaga T, Osaki A, Toge T. Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study. Breast Cancer Res Treat 1994;29:51-58 (Pubitemid 24104837)
35. Thor AD, Edgerton SM, Liu S, Moore DH II, Kwiatkowski DJ. Gelsolin as a negative prognostic factor and effector of motility in erbb-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res 2001;7:2415-2424 (Pubitemid 32751644)
36. Murali R, Brennan PJ, Kieber ET, Greene MI. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. Proc Natl Acad Sci U S A 1996;93:6252-6257 (Pubitemid 26230291)
37. Qian X, LeVea CM, Freeman JK, Dougall WC, Greene MI. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci U S A 1994;91:1500-1504 (Pubitemid 24059040)
38. GrausPorta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-1655 (Pubitemid 27151960)
39. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody-mediated intracellular retention of Erbb-2 impairs Neu differentiation factor and epidermal growth-factor signaling. Mol Cell Biol 1995;15:1182-1191
40. Brandt B, Kemming D, Packeisen J, et al. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility. Endocr Relat Cancer 2005;12:823-837 (Pubitemid 41815778)
41. Matsuda S, KawamuraTsuzuku J, Ohsugi M, et al. Tob, a novel protein that interacts with p185(erbB2), is associated with antiproliferative activity. Oncogene 1996;12:705-713 (Pubitemid 126423325)
42. Maekawa M, Nishida E, Tanoue T. Identification of the anti-proliferative protein Tob as a MAPK substrate. J Biol Chem 2002;277:37783-37787
43. Usui M, Yoshida Y, Yamashita T, et al. Enhancing effect of Tob deficiency on bone formation is specific to bone morphogenetic protein-induced osteogenesis. J Bone Miner Res 2002;17:1026-1033 (Pubitemid 34535140)
44. Suzuki T, Tsuzuku J, Ajima R, Nakamura T, Yoshida Y, Yamamoto T. Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev 2002;16:1356-1370 (Pubitemid 34615089)
45. Tzachanis D, Freeman GJ, Hirano N, et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2001;2:1174-1182 (Pubitemid 33130153)
46. Iwanaga K, Sueoka N, Sato A, et al. Alteration of expression or phosphorylation status of tob, a novel tumor suppressor gene product, is an early event in lung cancer. Cancer Lett 2003;202:71-79 (Pubitemid 37464900)
47. Yoshida Y, Nakamura T, Komoda M, et al. Mice lacking a transcriptional corepressor Tob are predisposed to cancer. Genes Dev 2003;17:1201-1206 (Pubitemid 36583162)
48. Ito Y, Suzuki T, Yoshida H, et al. Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. Cancer Lett 2005;220:237-242 (Pubitemid 40568781)
49. Iwanaga K, Sueoka N, Sato A, et al. Alteration of expression or phosphorylation status of tob, a novel tumor suppressor gene product, is an early event in lung cancer. Cancer Lett 2003;202:71-79 (Pubitemid 37464900)
50. Kawamura-Tsuzuku J, Suzuki T, Yoshida Y, Yamamoto T. Nuclear localization of Tob is important for regulation of its antiproliferative activity. Oncogene 2004;23:6630-6638 (Pubitemid 39265526)